felodipine has been researched along with Innate Inflammatory Response in 5 studies
Felodipine: A dihydropyridine calcium antagonist with positive inotropic effects. It lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels.
felodipine : The mixed (methyl, ethyl) diester of 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid. A calcium-channel blocker, it lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels. It is used in the management of hypertension and angina pectoris.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of a 6-week treatment with the AT1 receptor antagonist candesartan (16 mg/d) on endothelial function and serum inflammation markers was compared with the effect of treatment with placebo or the calcium channel antagonist felodipine (5 mg/d) in 47 hypercholesterolemic patients (low density lipoprotein cholesterol >160 mg/dL)." | 9.10 | Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction. ( Böhm, M; Hilgers, S; Laufs, U; Nickenig, G; Wassmann, S, 2002) |
| "The effect of a 6-week treatment with the AT1 receptor antagonist candesartan (16 mg/d) on endothelial function and serum inflammation markers was compared with the effect of treatment with placebo or the calcium channel antagonist felodipine (5 mg/d) in 47 hypercholesterolemic patients (low density lipoprotein cholesterol >160 mg/dL)." | 5.10 | Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction. ( Böhm, M; Hilgers, S; Laufs, U; Nickenig, G; Wassmann, S, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saunders, MJ | 1 |
| Edwards, BS | 1 |
| Zhu, J | 1 |
| Sklar, LA | 1 |
| Graves, SW | 1 |
| Kim, J | 1 |
| Jeon, SG | 1 |
| Jeong, HR | 1 |
| Park, H | 1 |
| Kim, JI | 1 |
| Hoe, HS | 1 |
| Xia, L | 1 |
| Yuan, LZ | 1 |
| Hu, YH | 1 |
| Liu, JY | 1 |
| Hu, GS | 1 |
| Qi, RY | 1 |
| Zhang, TY | 1 |
| Xiong, HL | 1 |
| Zheng, ZZ | 1 |
| Lin, HW | 1 |
| Zhang, JM | 1 |
| Yu, C | 1 |
| Zhou, M | 1 |
| Ma, J | 1 |
| Cheng, T | 1 |
| Chen, RR | 1 |
| Guan, Y | 1 |
| Xia, NS | 1 |
| Liu, W | 1 |
| Qi, J | 1 |
| Zheng, JB | 1 |
| Ai, WT | 1 |
| Yao, XW | 1 |
| Liang, L | 1 |
| Cheng, G | 1 |
| Shou, XL | 1 |
| Sun, CF | 1 |
| Wassmann, S | 1 |
| Hilgers, S | 1 |
| Laufs, U | 1 |
| Böhm, M | 1 |
| Nickenig, G | 1 |
1 trial available for felodipine and Innate Inflammatory Response
| Article | Year |
|---|---|
Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biomarker | 2002 |
4 other studies available for felodipine and Innate Inflammatory Response
| Article | Year |
|---|---|
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Pr | 2010 |
L-Type Ca
Topics: Animals; Dendritic Spines; Felodipine; Inflammation; Lipopolysaccharides; Mice; Mice, Inbred C57BL; | 2022 |
A SARS-CoV-2-specific CAR-T-cell model identifies felodipine, fasudil, imatinib, and caspofungin as potential treatments for lethal COVID-19.
Topics: Caspofungin; COVID-19; Cytokine Release Syndrome; Cytokines; Felodipine; Humans; Imatinib Mesylate; | 2023 |
Felodipine inhibits ox-LDL-induced reactive oxygen species production and inflammation in human umbilical vein endothelial cells.
Topics: Cells, Cultured; Felodipine; Gene Expression Regulation; Human Umbilical Vein Endothelial Cells; Hum | 2017 |